{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T09:30:27Z","timestamp":1791538227700,"version":"4.3.4"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Dev Behav Pediatr"],"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:title>ABSTRACT:<\/jats:title>\n          <jats:sec>\n            <jats:title>Objective:<\/jats:title>\n            <jats:p>To describe drug prescribing and outcomes after pharmacogenomic (PGx) testing in children with developmental and\/or behavioral disorders.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>This is a single-clinic retrospective analysis of patients aged 5 to 17 years with documented behavioral and\/or development disorder(s) and having received PGx testing between May 2015 and May 2017. The primary endpoint was frequency of PGx-guided medication changes after testing. Secondary endpoints included frequency of medications in each category from the PGx report (use as directed, use with caution, and use with increased caution), changes in therapy within each category, frequency and type of actionable genes, symptomatic improvement, and frequency of medication changes up to 6 months after PGx-guided therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Of 200 patients, 75% were male, 78% were white, 83% had attention-deficit\/hyperactivity disorder, and 45% had anxiety, and their mean age was 10 years. Most common reasons for ordering PGx testing were lack of response (83%) and\/or adverse events (42%). Approximately 84% had PGx-guided medication change(s) after testing. At baseline, 50% of medications were categorized in \u201cuse as directed,\u201d 40% in \u201cuse with caution,\u201d and 11% in \u201cuse with increased caution.\u201d After testing, 8%, 29%, and 30% of medications in \u201cuse as directed,\u201d \u201cuse with caution,\u201d and \u201cuse with increased caution\u201d categories were discontinued; 85% were added or continued from \u201cuse as directed\u201d category. The most common actionable genes were <jats:italic toggle=\"yes\">ADRA2A<\/jats:italic> (47%), <jats:italic toggle=\"yes\">COMT<\/jats:italic> (22%), and <jats:italic toggle=\"yes\">CYP2D6<\/jats:italic> (20%). Sixty percent were on the same medication(s) suggested by the PGx report 6 months later, and 64% had provider-documented symptomatic improvement.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Pharmacogenomic testing may affect drug prescribing and clinical outcomes in a pediatric behavioral health clinic.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/dbp.0000000000000746","type":"journal-article","created":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T19:28:56Z","timestamp":1572895736000},"page":"65-70","source":"Crossref","is-referenced-by-count":11,"title":["Drug Prescribing and Outcomes After Pharmacogenomic Testing in a Developmental and Behavioral Health Pediatric Clinic"],"prefix":"10.1097","volume":"41","author":[{"given":"Jai N.","family":"Patel","sequence":"first","affiliation":[{"name":"Departments of Cancer Pharmacology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxine K.","family":"Mueller","sequence":"additional","affiliation":[{"name":"Pharmacy, Levine Cancer Institute, Atrium Health, Charlotte, NC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Guffey","sequence":"additional","affiliation":[{"name":"Center for Advanced Practice, Atrium Health, Charlotte, NC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Stegman","sequence":"additional","affiliation":[{"name":"Developmental and Behavioral Pediatrics of the Carolinas, Atrium Health, Charlotte, NC."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230908","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jaac.2013.09.001","article-title":"Trends in the parent-report of health care provider-diagnosed and medicated attention-deficit\/hyperactivity disorder: United States, 2003-2011","volume":"53","author":"Visser","year":"2014","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R2-20230908","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.pedhc.2011.10.009","article-title":"Antipsychotic medication prescribing trends in children and adolescents","volume":"26","author":"Harrison","year":"2012","journal-title":"J Pediatr Health Care"},{"key":"R3-20230908","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1001\/jamapsychiatry.2013.3074","article-title":"National trends in the mental health care of children, adolescents, and adults by office-based physicians","volume":"71","author":"Olfson","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"R4-20230908","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1111\/j.1475-6773.2012.01461.x","article-title":"The relationship between mental health diagnosis and treatment with second-generation antipsychotics over time: a national study of U.S. Medicaid-enrolled children","volume":"47","author":"Matone","year":"2012","journal-title":"Health Serv Res"},{"key":"R5-20230908","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1056\/NEJMra1010600","article-title":"Genomics and drug response","volume":"364","author":"Wang","year":"2011","journal-title":"N Engl J Med"},{"key":"R6-20230908","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/cpt.709","article-title":"Pharmacogenomics\u2010based point\u2010of\u2010care clinical decision support significantly alters drug prescribing","volume":"102","author":"O'Donnell","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"R8-20230908","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/clpt.2010.279","article-title":"CPIC: Clinical Pharmacogenetics Implementation Consortium of the pharmacogenomics research network","volume":"89","author":"Relling","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"R9-20230908","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/phar.1398","article-title":"Pharmacogenomic testing for neuropsychiatric drugs: current status of drug labeling, guidelines for using genetic information, and test options","volume":"34","author":"Drozda","year":"2014","journal-title":"Pharmacotherapy"},{"key":"R10-20230908","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/clpt.2012.96","article-title":"Pharmacogenomics knowledge for personalized medicine","volume":"92","author":"Whirl-Carrillo","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"R11-20230908","first-page":"65","article-title":"Cancer pharmacogenomics, challenges in implementation, and patient-focused perspectives","volume":"9","author":"Patel","year":"2016","journal-title":"Pharmgenomics Pers Med"},{"key":"R12-20230908","first-page":"247","article-title":"Pharmacogenomic testing: aiding in the management of psychotropic therapy for adolescents with autism spectrum disorders","volume":"10","author":"Bose-Brill","year":"2017","journal-title":"Pharmgenomics Pers Med"},{"key":"R13-20230908","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/tpj.2014.85","article-title":"Clinical validity: combinatorial pharmacogenomics predicts antidepressant responses and healthcare utilizations better than single gene phenotypes","volume":"15","author":"Altar","year":"2015","journal-title":"Pharmacogenomics J"},{"key":"R14-20230908","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1186\/s12888-017-1412-1","article-title":"Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial","volume":"17","author":"Perez","year":"2017","journal-title":"BMC Psychiatry"},{"key":"R15-20230908","first-page":"219","article-title":"A prospective, randomized, double-blind study assessing the clinical impact of integrated pharmacogenomic testing for major depressive disorder","volume":"16","author":"Winner","year":"2013","journal-title":"Discov Med"},{"key":"R16-20230908","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jpsychires.2019.01.003","article-title":"Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: a large, patient- and rater-blinded, randomized, controlled study","volume":"111","author":"Greden","year":"2019","journal-title":"J Psychiatr Res"},{"key":"R17-20230908","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.mayocp.2016.02.023","article-title":"Pharmacokinetic pharmacogenetic prescribing guidelines for antidepressants: a template for psychiatric precision medicine","volume":"91","author":"Nassan","year":"2016","journal-title":"Mayo Clin Proc"},{"key":"R18-20230908","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12888-017-1230-5","article-title":"Antidepressant prescribing in the precision medicine era: a prescriber's primer on pharmacogenetic tools","volume":"17","author":"Bousman","year":"2017","journal-title":"BMC Psychiatry"},{"key":"R19-20230908","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/cpt.147","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors","volume":"98","author":"Hicks","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"R20-20230908","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/FPC.0000000000000173","article-title":"Escitalopram pharmacogenetics: CYP2C19 relationships with dosing and clinical outcomes in autism spectrum disorder","volume":"25","author":"Bishop","year":"2015","journal-title":"Pharmacogenet Genomics"},{"key":"R21-20230908","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00702-018-1882-4","article-title":"Clinical utility of pharmacogenetic testing in children and adolescents with severe mental disorders","volume":"126","author":"Blasco-Fontecilla","year":"2019","journal-title":"J Neural Transm (Vienna)"},{"key":"R22-20230908","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1089\/cap.2006.0144","article-title":"Serotonin transporter polymorphism (5-HTTLPR) and citalopram effectiveness and side effects in children with depression and\/or anxiety disorders","volume":"17","author":"Kronenberg","year":"2007","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R23-20230908","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.3390\/ijms16034416","article-title":"Pharmacogenetics informed decision making in adolescent psychiatric treatment: a clinical case report","volume":"16","author":"Smith","year":"2015","journal-title":"Int J Mol Sci"},{"key":"R24-20230908","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/clpt.2013.254","article-title":"Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update","volume":"95","author":"Crews","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"R25-20230908","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/cpt.1304","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update","volume":"105","author":"Relling","year":"2019","journal-title":"Clin Pharmacol Ther"},{"key":"R26-20230908","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/cpt.1004","article-title":"Clinical Pharmacogenetics Implementation Consortium guideline for HLA genotype and use of carbamazepine and oxcarbazepine: 2017 update","volume":"103","author":"Phillips","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"R27-20230908","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1177\/0009922814533186","article-title":"Clinically relevant pharmacogenomic testing in pediatric practice","volume":"53","author":"Korbel","year":"2014","journal-title":"Clin Pediatr (Phila)"},{"key":"R28-20230908","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1002\/cpt.1035","article-title":"Benefit of preemptive pharmacogenetic information on clinical outcome","volume":"103","author":"Roden","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"R29-20230908","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1146\/annurev-pharmtox-010814-124835","article-title":"Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers","volume":"55","author":"Dunnenberger","year":"2015","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"R30-20230908","doi-asserted-by":"crossref","first-page":"e20161573","DOI":"10.1542\/peds.2016-1573","article-title":"Evaluation and management of children with acute mental health or behavioral problems. Part II: recognition of clinically challenging mental health related conditions presenting with medical or uncertain symptoms","volume":"138","author":"Chun","year":"2016","journal-title":"Pediatrics"}],"container-title":["Journal of Developmental &amp; Behavioral Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/DBP.0000000000000746","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T06:08:04Z","timestamp":1694153284000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/DBP.0000000000000746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/dbp.0000000000000746","relation":{},"ISSN":["0196-206X"],"issn-type":[{"value":"0196-206X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]}}}